Jevon Johnson, MD
Psychiatry · Modesto, CANPI 1154512036
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,084 of the $106,445 with a category attached, or 76.2%. Otsuka America Pharmaceutical, Inc. accounts for 78.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $34,104 and has fallen 95.6% since, to $1,512 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $205.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$84K
- Indivior Inc.$15K
- Johnson & Johnson$1K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$877
- Vanda Pharmaceuticals Inc.$816
- plus $3K from 8 others
What the payments were for
- Consulting fees$4,9865%
- Speaking & faculty fees$81,08476%
- Travel & lodging$9,0108%
- Food & beverage$11,01410%
- Education$3510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 249 | $83,957 |
| Indivior Inc. | 68 | $15,458 |
| Johnson & Johnson | 61 | $1,411 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $1,303 |
| Teva Pharmaceuticals USA, Inc. | 24 | $877 |
| Vanda Pharmaceuticals Inc. | 27 | $816 |
| Alkermes, Inc. | 25 | $755 |
| Lundbeck LLC | 11 | $612 |
| AbbVie | 22 | $532 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $408 |
| E.r. Squibb & Sons, L.L.C. | 6 | $218 |
| Boehringer Ingelheim | 1 | $62 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
| Luye Pharma (USA) Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$74,334
- PERSERIS$13,930
- REXULTI$6,059
- ABILIFY ASIMTUFII$1,200
- ARISTADA$455
- UZEDY$128
- LYBALVI$114
- COBENFY$106
How this compares
$106,445 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 15 | $43,464 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $22,614 |
| VraylarCariprazine Hcl | 13 | $18,044 |
| Clozapine | 42 | $2,647 |
| Divalproex Sodium ErDivalproex Sodium | 40 | $2,268 |
| Olanzapine | 29 | $1,443 |
| Paliperidone ErPaliperidone | 11 | $1,008 |
| Ziprasidone Hcl | 14 | $926 |
| Lurasidone Hcl | 14 | $919 |
| Buspirone Hcl | 28 | $662 |
| Benztropine Mesylate | 39 | $601 |
| Risperidone | 19 | $474 |
| Haloperidol | 13 | $367 |
| Quetiapine Fumarate | 34 | $339 |
| Clonazepam | 25 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $83,957 | $43,46415 claims |
| Alkermes, Inc.Lybalvi | $755 | $22,61414 claims |
| AbbVieVraylar | $532 | $18,04413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Modesto
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.